OVERVIEW

FLT3 Targets in R/R AML: Evaluating Emerging Clinical Data and Implications on Current Practice is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.
Accreditation:
1.50 CME
1.50 CNE
1.50 CPE

Course Overview:
In 2018, an estimated 19,520 new cases of acute myeloid leukemia (AML) will be diagnosed and approximately 10,670 deaths will be attributed to AML—representing the leading cause of mortality among all leukemias. While high complete response (CR) rates in AML are achievable, the majority of patients will ultimately be diagnosed with relapsed or refractory disease. The management of relapsed/refractory (R/R) AML imposes significant challenges to practice as cure rates no greater than 10% have been documented. A number of novel targeted agents have shown promise within the treatment of patient populations with FLT3-mutation positive R/R disease. However, gaps in provider knowledge may preclude their proper use within clinical practice once available.

This on-demand web archive is initiated to address such R/R AML-related knowledge and practice gaps among physicians, NPs, and PAs who manage patients with hematologic malignancies.

Course Objectives:
• Identify the challenges associated with the treatment of R/R AML, including mechanisms of resistance, molecular and cytogenic aberrations, and patient age/fitness
• Describe the mechanisms and genetic targets involved in hematologic neoplasms and AML in particular
• Evaluate clinical evidence and outcomes data surrounding new and emerging targeted therapies for the treatment in R/R AML
• Integrate new and emerging targeted agents into personalized R/R AML treatment plans

Additional details will be posted as soon as they are available.